Detalhe da pesquisa
1.
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Int J Gynecol Cancer
; 34(4): 550-558, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38129136
2.
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study.
Oncologist
; 28(12): e1152-e1159, 2023 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37555463
3.
Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group.
Arch Gynecol Obstet
; 301(5): 1267-1274, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32277253
4.
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial.
Br J Cancer
; 121(12): 1009-1015, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31728025
5.
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
Int J Gynecol Cancer
; 29(7): 1141-1147, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31420414
6.
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
Breast Cancer Res Treat
; 161(1): 63-72, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27798749
7.
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Gynecol Oncol
; 144(1): 65-71, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27871723
8.
Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
Gynecol Oncol
; 140(3): 450-6, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26731724
9.
Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7).
Int J Gynecol Cancer
; 26(9): 1636-1641, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27654266
10.
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Breast Cancer Res Treat
; 149(1): 141-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25519041
11.
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
Geburtshilfe Frauenheilkd
; 84(2): e10, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38690326
12.
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
Geburtshilfe Frauenheilkd
; 84(2): 185-195, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38344045
13.
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Breast Cancer Res Treat
; 139(3): 779-87, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23771714
14.
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.
Clin Cancer Res
; 29(21): 4419-4429, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37756555
15.
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
J Clin Oncol
; 41(4): 893-902, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332161
16.
Mitomycin C in combination with vinorelbine in anthracycline- and/or taxane-pretreated patients with metastatic breast cancer.
Onkologie
; 35(9): 500-4, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23007147
17.
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study.
Breast
; 66: 110-117, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36223695
18.
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.
BMC Cancer
; 11: 131, 2011 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-21486442
19.
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
Eur J Cancer
; 156: 138-148, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34450552
20.
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer.
BMC Cancer
; 10: 2, 2010 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-20047698